| 摘要 |
Compounds of formula (I); wherein R<SUB>1 </SUB>is H or NHZ; R<SUB>2 </SUB>is optionally substituted aryl or heteroaryl attached via a carbon atom; R<SUB>3 </SUB>is H; optionally substituted C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, C<SUB>2</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6</SUB>alkynyl, or C<SUB>3 </SUB>C<SUB>7 </SUB>cycloalkyl, halogen; OH or OR, or R<SUB>4 </SUB>is H, optionally substituted C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, C<SUB>3 </SUB>C<SUB>6</SUB>alkenyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkynyl, C<SUB>3</SUB>-C<SUB>7 </SUB>cycloalkyl, aryl or heteroaryl, R<SUB>5 </SUB>is H or optionally substituted C<SUB>1</SUB>-C<SUB>6</SUB>alkyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkenyl, C<SUB>3</SUB>-C<SUB>6</SUB>alkynyl, or C<SUB>3</SUB>-C<SUB>7 </SUB>cycloalkyl; or R<SUB>4 </SUB>and R<SUB>5 </SUB>together form a 5 or 6-membered heterocyclic ring; and R<SUB>10 </SUB>is optionally substituted C<SUB>1</SUB>-C<SUB>6</SUB>alkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease.
|
